[Results of controlled tests of an experimental recombinant live vaccine against hepatitis B].
Experimental recombinant vaccine against hepatitis B Revacc B based on vaccinia virus has been tried. The preparation was weakly reactogenic but did not induce the production of anti-HBasAg antibodies. On the other hand, recombinant vaccine against hepatitis B Engerix B, used in a blind experiment as the agent of comparison, induced the production of anti-HBs in 91% of vaccinees.
Ikoev
V N
VN
Gorbunov
M A
MA
Bektimirov
T A
TA
Noskova
A V
AV
Perekrest
V V
VV
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D018849:Controlled Clinical Trials as Topic; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic